{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:13:56Z","timestamp":1793834036049,"version":"4.6.1"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12885-016-2999-1","type":"journal-article","created":{"date-parts":[[2017,1,5]],"date-time":"2017-01-05T05:19:24Z","timestamp":1483593564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":307,"title":["Molecular chess? Hallmarks of anti-cancer drug resistance"],"prefix":"10.1186","volume":"17","author":[{"given":"Ian A.","family":"Cree","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Charlton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,5]]},"reference":[{"issue":"5","key":"2999_CR1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1001\/jama.1946.02870400011003","volume":"132","author":"LO Jacobson","year":"1946","unstructured":"Jacobson LO, Spurr CL, Guzman ES, Barron ES, Smith T, Lushbaugh C, Dick GF. Nitrogen mustard therapy. Studies on the Effect of Methyl-Bis (Beta-Chloroethyl) Amine Hydrochloride on Neoplastic Diseases and Allied Disorders of the Hemopoietic System. JAMA. 1946;132(5):263\u201371.","journal-title":"JAMA"},{"key":"2999_CR2","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1001\/jama.1946.02870250010003","volume":"131","author":"CP Rhoads","year":"1946","unstructured":"Rhoads CP. Nitrogen mustards in the treatment of neoplastic disease. JAMA. 1946;131:656\u20138.","journal-title":"JAMA"},{"key":"2999_CR3","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/jama.1946.02870380008004","volume":"132","author":"LS Goodman","year":"1946","unstructured":"Goodman LS, Wintrobe MM, et al. Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin\u2019s disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J Am Med Assoc. 1946;132:126\u201332.","journal-title":"J Am Med Assoc"},{"issue":"6","key":"2999_CR4","first-page":"390","volume":"15","author":"GL Woodside","year":"1955","unstructured":"Woodside GL, Kelton DE. Combination chemotherapy of mouse tumors with 8-azaguanine and flavotin. Cancer Res. 1955;15(6):390\u20133.","journal-title":"Cancer Res"},{"issue":"3","key":"2999_CR5","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/j.1749-6632.1958.tb54909.x","volume":"76","author":"N Mantel","year":"1958","unstructured":"Mantel N. An experimental design in combination chemotherapy. Ann N Y Acad Sci. 1958;76(3):909\u201314. discussion 915\u201331.","journal-title":"Ann N Y Acad Sci"},{"issue":"12","key":"2999_CR6","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V13.12.1126.1126","volume":"13","author":"E Frei 3rd","year":"1958","unstructured":"Frei 3rd E, et al. A comparative study of two regimens of combination chemotherapy in acute leukemia. Blood. 1958;13(12):1126\u201348.","journal-title":"Blood"},{"issue":"4","key":"2999_CR7","first-page":"634","volume":"3","author":"IA Cree","year":"2002","unstructured":"Cree IA, et al. Chemosensitization of solid tumors by modulation of resistance mechanisms. Curr Opin Investig Drugs. 2002;3(4):634\u201340.","journal-title":"Curr Opin Investig Drugs"},{"issue":"4","key":"2999_CR8","first-page":"641","volume":"3","author":"IA Cree","year":"2002","unstructured":"Cree IA, et al. Chemosensitization of solid tumor cells by alteration of their susceptibility to apoptosis. Curr Opin Investig Drugs. 2002;3(4):641\u20137.","journal-title":"Curr Opin Investig Drugs"},{"issue":"6090","key":"2999_CR9","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/323728a0","volume":"323","author":"P Gros","year":"1986","unstructured":"Gros P, et al. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature. 1986;323(6090):728\u201331.","journal-title":"Nature"},{"issue":"3","key":"2999_CR10","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/1479-7364-3-3-281","volume":"3","author":"V Vasiliou","year":"2009","unstructured":"Vasiliou V, Vasiliou K, Nebert DW. Human ATP-binding cassette (ABC) transporter family. Hum Genomics. 2009;3(3):281\u201390.","journal-title":"Hum Genomics"},{"issue":"6","key":"2999_CR11","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/00001813-199608000-00002","volume":"7","author":"IA Cree","year":"1996","unstructured":"Cree IA, et al. Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anticancer Drugs. 1996;7(6):630\u20135.","journal-title":"Anticancer Drugs"},{"key":"2999_CR12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1471-2407-5-78","volume":"5","author":"F Nicolantonio Di","year":"2005","unstructured":"Di Nicolantonio F, et al. Cancer cell adaptation to chemotherapy. BMC Cancer. 2005;5:78.","journal-title":"BMC Cancer"},{"issue":"11","key":"2999_CR13","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/jcp.2010.080119","volume":"63","author":"KA Parker","year":"2010","unstructured":"Parker KA, et al. The molecular basis of the chemosensitivity of metastatic cutaneous melanoma to chemotherapy. J Clin Pathol. 2010;63(11):1012\u201320.","journal-title":"J Clin Pathol"},{"issue":"5","key":"2999_CR14","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/sj.bjc.6605817","volume":"103","author":"S Glaysher","year":"2010","unstructured":"Glaysher S, et al. Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy. Br J Cancer. 2010;103(5):656\u201362.","journal-title":"Br J Cancer"},{"key":"2999_CR15","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/1471-2407-9-300","volume":"9","author":"S Glaysher","year":"2009","unstructured":"Glaysher S, et al. Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC). BMC Cancer. 2009;9:300.","journal-title":"BMC Cancer"},{"issue":"6","key":"2999_CR16","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1245\/s10434-013-3373-z","volume":"21","author":"DM Bello","year":"2014","unstructured":"Bello DM, Dematteo RP, Ariyan CE. The GIST of targeted therapy for malignant melanoma. Ann Surg Oncol. 2014;21(6):2059\u201367.","journal-title":"Ann Surg Oncol"},{"issue":"Suppl 5","key":"2999_CR17","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/S0959-8049(02)80603-7","volume":"38","author":"GD Demetri","year":"2002","unstructured":"Demetri GD. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). Eur J Cancer. 2002;38 Suppl 5:S52\u20139.","journal-title":"Eur J Cancer"},{"issue":"27","key":"2999_CR18","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1038\/sj.onc.1210173","volume":"26","author":"D Mahadevan","year":"2007","unstructured":"Mahadevan D, et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene. 2007;26(27):3909\u201319.","journal-title":"Oncogene"},{"issue":"5 Suppl 17","key":"2999_CR19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/sonc.2001.29181","volume":"28","author":"GD Demetri","year":"2001","unstructured":"Demetri GD. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin Oncol. 2001;28(5 Suppl 17):19\u201326.","journal-title":"Semin Oncol"},{"issue":"6","key":"2999_CR20","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11864-002-0068-2","volume":"3","author":"S George","year":"2002","unstructured":"George S, Desai J. Management of gastrointestinal stromal tumors in the era of tyrosine kinase inhibitors. Curr Treat Options Oncol. 2002;3(6):489\u201396.","journal-title":"Curr Treat Options Oncol"},{"issue":"11","key":"2999_CR21","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1158\/1078-0432.CCR-04-2245","volume":"11","author":"CR Antonescu","year":"2005","unstructured":"Antonescu CR, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005;11(11):4182\u201390.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2999_CR22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.semdp.2006.08.006","volume":"23","author":"J Lasota","year":"2006","unstructured":"Lasota J, Miettinen M. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Semin Diagn Pathol. 2006;23(2):91\u2013102.","journal-title":"Semin Diagn Pathol"},{"issue":"6","key":"2999_CR23","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1158\/1078-0432.CCR-05-1211","volume":"12","author":"E Wardelmann","year":"2006","unstructured":"Wardelmann E, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res. 2006;12(6):1743\u20139.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"2999_CR24","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1007\/s00280-010-1526-3","volume":"67","author":"MM Gounder","year":"2011","unstructured":"Gounder MM, Maki RG. Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. Cancer Chemother Pharmacol. 2011;67 Suppl 1:S25\u201343.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"21","key":"2999_CR25","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129\u201339.","journal-title":"N Engl J Med"},{"issue":"16","key":"2999_CR26","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.1158\/0008-5472.CAN-05-1346","volume":"65","author":"S Kobayashi","year":"2005","unstructured":"Kobayashi S, et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 2005;65(16):7096\u2013101.","journal-title":"Cancer Res"},{"issue":"21","key":"2999_CR27","doi-asserted-by":"crossref","first-page":"7060","DOI":"10.1158\/1078-0432.CCR-08-1455","volume":"14","author":"DB Costa","year":"2008","unstructured":"Costa DB, et al. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res. 2008;14(21):7060\u20137.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2999_CR28","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/annonc\/mdt205","volume":"24","author":"S Dearden","year":"2013","unstructured":"Dearden S, et al. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013;24(9):2371\u20136.","journal-title":"Ann Oncol"},{"issue":"7326","key":"2999_CR29","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","volume":"468","author":"R Nazarian","year":"2010","unstructured":"Nazarian R, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468(7326):973\u20137.","journal-title":"Nature"},{"issue":"5","key":"2999_CR30","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/annonc\/mdu049","volume":"25","author":"S Turajlic","year":"2014","unstructured":"Turajlic S, et al. Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Ann Oncol. 2014;25(5):959\u201367.","journal-title":"Ann Oncol"},{"issue":"8","key":"2999_CR31","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.ctrv.2013.02.006","volume":"39","author":"P De","year":"2013","unstructured":"De P, Hasmann M, Leyland-Jones B. Molecular determinants of trastuzumab efficacy: What is their clinical relevance? Cancer Treat Rev. 2013;39(8):925\u201334.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"2999_CR32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/nrclinonc.2011.177","volume":"9","author":"CL Arteaga","year":"2012","unstructured":"Arteaga CL, et al. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2012;9(1):16\u201332.","journal-title":"Nat Rev Clin Oncol"},{"key":"2999_CR33","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.critrevonc.2016.01.024","volume":"100","author":"AJ Wekken van der","year":"2016","unstructured":"van der Wekken AJ, et al. Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature. Crit Rev Oncol Hematol. 2016;100:107\u201316.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"2999_CR34","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S1470-2045(14)71180-5","volume":"16","author":"MG Oser","year":"2015","unstructured":"Oser MG, et al. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015;16(4):e165\u201372.","journal-title":"Lancet Oncol"},{"issue":"7","key":"2999_CR35","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/cncy.21281","volume":"121","author":"NV Mitiushkina","year":"2013","unstructured":"Mitiushkina NV, et al. Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides. Cancer Cytopathol. 2013;121(7):370\u20136.","journal-title":"Cancer Cytopathol"},{"issue":"4","key":"2999_CR36","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/JTO.0b013e318283dcc0","volume":"8","author":"S Kim","year":"2013","unstructured":"Kim S, et al. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. J Thorac Oncol. 2013;8(4):415\u201322.","journal-title":"J Thorac Oncol"},{"key":"2999_CR37","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.2741\/3823","volume":"16","author":"NA Colabufo","year":"2011","unstructured":"Colabufo NA, et al. EGFR tyrosine kinase inhibitors and multidrug resistance: perspectives. Front Biosci (Landmark Ed). 2011;16:1811\u201323.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"2","key":"2999_CR38","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00280-009-1039-0","volume":"65","author":"A Azzariti","year":"2010","unstructured":"Azzariti A, et al. Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences. Cancer Chemother Pharmacol. 2010;65(2):335\u201346.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"2999_CR39","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/1097-0142(19920215)69:4<941::AID-CNCR2820690418>3.0.CO;2-H","volume":"69","author":"T Satta","year":"1992","unstructured":"Satta T, et al. Expression of MDR1 and glutathione S transferase-pi genes and chemosensitivities in human gastrointestinal cancer. Cancer. 1992;69(4):941\u20136.","journal-title":"Cancer"},{"issue":"1","key":"2999_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-014-2566-x","volume":"75","author":"S Singh","year":"2015","unstructured":"Singh S. Cytoprotective and regulatory functions of glutathione S-transferases in cancer cell proliferation and cell death. Cancer Chemother Pharmacol. 2015;75(1):1\u201315.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"2999_CR41","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1517\/17425250903427980","volume":"6","author":"G Pietro Di","year":"2010","unstructured":"Di Pietro G, Magno LA, Rios-Santos F. Glutathione S-transferases: an overview in cancer research. Expert Opin Drug Metab Toxicol. 2010;6(2):153\u201370.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"7","key":"2999_CR42","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2174\/187152009789056895","volume":"9","author":"P Ruzza","year":"2009","unstructured":"Ruzza P, et al. Glutathione transferases as targets for cancer therapy. Anticancer Agents Med Chem. 2009;9(7):763\u201377.","journal-title":"Anticancer Agents Med Chem"},{"issue":"8","key":"2999_CR43","doi-asserted-by":"crossref","first-page":"6431","DOI":"10.18632\/oncotarget.3237","volume":"6","author":"W Hassen","year":"2015","unstructured":"Hassen W, et al. Drug metabolism and clearance system in tumor cells of patients with multiple myeloma. Oncotarget. 2015;6(8):6431\u201347.","journal-title":"Oncotarget"},{"key":"2999_CR44","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0074-7696(08)62312-8","volume":"68","author":"AH Wyllie","year":"1980","unstructured":"Wyllie AH, Kerr JF, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol. 1980;68:251\u2013306.","journal-title":"Int Rev Cytol"},{"issue":"4","key":"2999_CR45","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/bjc.1972.33","volume":"26","author":"JF Kerr","year":"1972","unstructured":"Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26(4):239\u201357.","journal-title":"Br J Cancer"},{"issue":"14","key":"2999_CR46","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1002\/j.1460-2075.1994.tb06630.x","volume":"13","author":"EA Harrington","year":"1994","unstructured":"Harrington EA, et al. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J. 1994;13(14):3286\u201395.","journal-title":"EMBO J"},{"issue":"2","key":"2999_CR47","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/path.1706","volume":"205","author":"DB Longley","year":"2005","unstructured":"Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005;205(2):275\u201392.","journal-title":"J Pathol"},{"issue":"3","key":"2999_CR48","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/bcr289","volume":"3","author":"G Makin","year":"2001","unstructured":"Makin G, Dive C. Modulating sensitivity to drug-induced apoptosis: the future for chemotherapy? Breast Cancer Res. 2001;3(3):150\u20133.","journal-title":"Breast Cancer Res"},{"issue":"15","key":"2999_CR49","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.2174\/09298673113209990106","volume":"20","author":"G Cassinelli","year":"2013","unstructured":"Cassinelli G, et al. Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells. Curr Med Chem. 2013;20(15):1923\u201345.","journal-title":"Curr Med Chem"},{"key":"2999_CR50","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1186\/1756-0500-7-397","volume":"7","author":"S Glaysher","year":"2014","unstructured":"Glaysher S, et al. Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model. BMC Res Notes. 2014;7:397.","journal-title":"BMC Res Notes"},{"issue":"7","key":"2999_CR51","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1038\/bjc.2013.529","volume":"109","author":"S Glaysher","year":"2013","unstructured":"Glaysher S, et al. Targeting EGFR and PI3K pathways in ovarian cancer. Br J Cancer. 2013;109(7):1786\u201394.","journal-title":"Br J Cancer"},{"issue":"1","key":"2999_CR52","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/cdd.2008.150","volume":"16","author":"G Kroemer","year":"2009","unstructured":"Kroemer G, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009;16(1):3\u201311.","journal-title":"Cell Death Differ"},{"issue":"5","key":"2999_CR53","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.bcp.2011.06.015","volume":"82","author":"A Notte","year":"2011","unstructured":"Notte A, Leclere L, Michiels C. Autophagy as a mediator of chemotherapy-induced cell death in cancer. Biochem Pharmacol. 2011;82(5):427\u201334.","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"2999_CR54","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.bbamcr.2009.01.006","volume":"1793","author":"E Morselli","year":"2009","unstructured":"Morselli E, et al. Anti- and pro-tumor functions of autophagy. Biochim Biophys Acta. 2009;1793(9):1524\u201332.","journal-title":"Biochim Biophys Acta"},{"key":"2999_CR55","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-015-0321-5","volume":"14","author":"Z Su","year":"2015","unstructured":"Su Z, et al. Apoptosis, autophagy, necroptosis, and cancer metastasis. Mol Cancer. 2015;14:48.","journal-title":"Mol Cancer"},{"issue":"12","key":"2999_CR56","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1002\/jcb.25229","volume":"116","author":"J Wesierska-Gadek","year":"2015","unstructured":"Wesierska-Gadek J, et al. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells. J Cell Biochem. 2015;116(12):2824\u201339.","journal-title":"J Cell Biochem"},{"issue":"17","key":"2999_CR57","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1158\/1078-0432.CCR-15-0088","volume":"21","author":"KS Tewari","year":"2015","unstructured":"Tewari KS, Eskander RN, Monk BJ. Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer. Clin Cancer Res. 2015;21(17):3829\u201335.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2999_CR58","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11864-015-0378-9","volume":"17","author":"FW Liu","year":"2016","unstructured":"Liu FW, Tewari KS. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors. Curr Treat Options Oncol. 2016;17(3):12.","journal-title":"Curr Treat Options Oncol"},{"key":"2999_CR59","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3389\/fonc.2014.00285","volume":"4","author":"J Pflaum","year":"2014","unstructured":"Pflaum J, Schlosser S, Muller M. p53 Family and Cellular Stress Responses in Cancer. Front Oncol. 2014;4:285.","journal-title":"Front Oncol"},{"issue":"5","key":"2999_CR60","doi-asserted-by":"crossref","first-page":"710","DOI":"10.4161\/cc.28108","volume":"13","author":"JM Beckta","year":"2014","unstructured":"Beckta JM, et al. Revisiting p53 for cancer-specific chemo- and radiotherapy: ten years after. Cell Cycle. 2014;13(5):710\u20133.","journal-title":"Cell Cycle"},{"issue":"1","key":"2999_CR61","doi-asserted-by":"crossref","first-page":"e86459","DOI":"10.1371\/journal.pone.0086459","volume":"9","author":"A Murakami","year":"2014","unstructured":"Murakami A, et al. Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor. PLoS One. 2014;9(1):e86459.","journal-title":"PLoS One"},{"issue":"1","key":"2999_CR62","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/1574888X113089990053","volume":"9","author":"B Bao","year":"2014","unstructured":"Bao B, et al. Targeting CSCs in tumor microenvironment: the potential role of ROS-associated miRNAs in tumor aggressiveness. Curr Stem Cell Res Ther. 2014;9(1):22\u201335.","journal-title":"Curr Stem Cell Res Ther"},{"issue":"5","key":"2999_CR63","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4161\/auto.4311","volume":"3","author":"JS Carew","year":"2007","unstructured":"Carew JS, Nawrocki ST, Cleveland JL. Modulating autophagy for therapeutic benefit. Autophagy. 2007;3(5):464\u20137.","journal-title":"Autophagy"},{"issue":"3","key":"2999_CR64","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/bjc.2012.581","volume":"108","author":"R Fisher","year":"2013","unstructured":"Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer. 2013;108(3):479\u201385.","journal-title":"Br J Cancer"},{"issue":"1","key":"2999_CR65","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2001-1326-2-3","volume":"2","author":"LN Abdullah","year":"2013","unstructured":"Abdullah LN, Chow EK. Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med. 2013;2(1):3.","journal-title":"Clin Transl Med"},{"key":"2999_CR66","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1186\/1471-2164-15-711","volume":"15","author":"SF Vencken","year":"2014","unstructured":"Vencken SF, et al. An integrated analysis of the SOX2 microRNA response program in human pluripotent and nullipotent stem cell lines. BMC Genomics. 2014;15:711.","journal-title":"BMC Genomics"},{"issue":"5","key":"2999_CR67","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/ncb2960","volume":"16","author":"N Kannan","year":"2014","unstructured":"Kannan N, Nguyen LV, Eaves CJ. Integrin beta3 links therapy resistance and cancer stem cell properties. Nat Cell Biol. 2014;16(5):397\u20139.","journal-title":"Nat Cell Biol"},{"issue":"21","key":"2999_CR68","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.4161\/cc.9.21.13817","volume":"9","author":"UE Martinez-Outschoorn","year":"2010","unstructured":"Martinez-Outschoorn UE, et al. The autophagic tumor stroma model of cancer or \u201cbattery-operated tumor growth\u201d: A simple solution to the autophagy paradox. Cell Cycle. 2010;9(21):4297\u2013306.","journal-title":"Cell Cycle"},{"issue":"1","key":"2999_CR69","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/abbs\/gmv103","volume":"48","author":"N Zhang","year":"2016","unstructured":"Zhang N, et al. HER3\/ErbB3, an emerging cancer therapeutic target. Acta Biochim Biophys Sin Shanghai. 2016;48(1):39\u201348.","journal-title":"Acta Biochim Biophys Sin Shanghai"},{"issue":"2","key":"2999_CR70","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.str.2014.11.019","volume":"23","author":"EM Huber","year":"2015","unstructured":"Huber EM, Heinemeyer W, Groll M. Bortezomib-resistant mutant proteasomes: structural and biochemical evaluation with carfilzomib and ONX 0914. Structure. 2015;23(2):407\u201317.","journal-title":"Structure"},{"issue":"1","key":"2999_CR71","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1124\/jpet.111.187542","volume":"341","author":"SE Verbrugge","year":"2012","unstructured":"Verbrugge SE, et al. Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein\/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis. J Pharmacol Exp Ther. 2012;341(1):174\u201382.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"2999_CR72","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1517\/14728214.2016.1146680","volume":"21","author":"G Awada","year":"2016","unstructured":"Awada G, et al. Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer. Expert Opin Emerg Drugs. 2016;21(1):91\u2013101.","journal-title":"Expert Opin Emerg Drugs"},{"key":"2999_CR73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17425255.2016.1196186","volume":"12","author":"M Niazi","year":"2016","unstructured":"Niazi M, et al. Nano-based strategies to overcome p-glycoprotein-mediated drug resistance. Expert Opin Drug Metab Toxicol. 2016;12:1\u201313.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"2999_CR74","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1158\/1078-0432.CCR-07-2219","volume":"14","author":"J Bennouna","year":"2008","unstructured":"Bennouna J, et al. Vinflunine: a new microtubule inhibitor agent. Clin Cancer Res. 2008;14(6):1625\u201332.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2999_CR75","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2174\/1381612013397456","volume":"7","author":"BT Hill","year":"2001","unstructured":"Hill BT. Vinflunine, a second generation novel Vinca Alkaloid with a distinctive pharmacological profile, now in clinical development and prospects for future mitotic blockers. Curr Pharm Des. 2001;7(13):1199\u2013212.","journal-title":"Curr Pharm Des"},{"issue":"4","key":"2999_CR76","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.coph.2010.05.001","volume":"10","author":"IA Cree","year":"2010","unstructured":"Cree IA, Glaysher S, Harvey AL. Efficacy of anti-cancer agents in cell lines versus human primary tumour tissue. Curr Opin Pharmacol. 2010;10(4):375\u20139.","journal-title":"Curr Opin Pharmacol"},{"issue":"6","key":"2999_CR77","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/bio.1170090604","volume":"9","author":"PE Andreotti","year":"1994","unstructured":"Andreotti PE, et al. TCA-100 tumour chemosensitivity assay: differences in sensitivity between cultured tumour cell lines and clinical studies. J Biolumin Chemilumin. 1994;9(6):373\u20138.","journal-title":"J Biolumin Chemilumin"},{"issue":"2","key":"2999_CR78","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jconrel.2013.07.007","volume":"172","author":"IA Cree","year":"2013","unstructured":"Cree IA. Designing personalised cancer treatments. J Control Release. 2013;172(2):405\u20139.","journal-title":"J Control Release"},{"issue":"9","key":"2999_CR79","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ctrv.2015.06.008","volume":"41","author":"CA Cella","year":"2015","unstructured":"Cella CA, et al. Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: from bench to bedside. Cancer Treat Rev. 2015;41(9):754\u201360.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"2999_CR80","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12885-015-1015-5","volume":"15","author":"B Tops","year":"2015","unstructured":"Tops B, et al. Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium. BMC Cancer. 2015;15(1):26.","journal-title":"BMC Cancer"},{"issue":"1","key":"2999_CR81","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2041-9414-4-5","volume":"4","author":"KR Luoto","year":"2013","unstructured":"Luoto KR, Kumareswaran R, Bristow RG. Tumor hypoxia as a driving force in genetic instability. Genome Integr. 2013;4(1):5.","journal-title":"Genome Integr"},{"issue":"1","key":"2999_CR82","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1006\/bbrc.1994.1223","volume":"199","author":"RD Petty","year":"1994","unstructured":"Petty RD, et al. Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity. Biochem Biophys Res Commun. 1994;199(1):264\u201370.","journal-title":"Biochem Biophys Res Commun"},{"key":"2999_CR83","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.drup.2015.11.005","volume":"24","author":"NG Alkema","year":"2016","unstructured":"Alkema NG, et al. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions. Drug Resist Updat. 2016;24:55\u201369.","journal-title":"Drug Resist Updat"},{"issue":"1","key":"2999_CR84","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/MJT.0b013e31829e885c","volume":"22","author":"E Espinosa","year":"2015","unstructured":"Espinosa E, et al. Treatment algorithms in stage IV melanoma. Am J Ther. 2015;22(1):61\u20137.","journal-title":"Am J Ther"},{"issue":"7547","key":"2999_CR85","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor C, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373\u20137.","journal-title":"Nature"},{"issue":"2","key":"2999_CR86","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/his.12996","volume":"69","author":"IA Cree","year":"2016","unstructured":"Cree IA, et al. PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. Histopathology. 2016;69(2):177\u201386.","journal-title":"Histopathology"},{"issue":"6230","key":"2999_CR87","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124\u20138.","journal-title":"Science"},{"key":"2999_CR88","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40425-016-0153-x","volume":"4","author":"C Grigg","year":"2016","unstructured":"Grigg C, Rizvi NA. PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? J Immunother Cancer. 2016;4:48.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2999_CR89","doi-asserted-by":"crossref","first-page":"e1048929","DOI":"10.1080\/23723556.2015.1048929","volume":"3","author":"M Hellmann","year":"2016","unstructured":"Hellmann M, et al. Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma. Mol Cell Oncol. 2016;3(1):e1048929.","journal-title":"Mol Cell Oncol"},{"key":"2999_CR90","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1136\/jclinpath-2014-202404","volume":"67","author":"IA Cree","year":"2014","unstructured":"Cree IA, et al. Guidance for laboratories performing molecular pathology for cancer patients. J Clin Pathol. 2014;67:923\u201331.","journal-title":"J Clin Pathol"},{"issue":"4","key":"2999_CR91","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/PDM.0b013e318294936c","volume":"22","author":"EC Young","year":"2013","unstructured":"Young EC, et al. A comparison of methods for EGFR mutation testing in non-small cell lung cancer. Diagn Mol Pathol. 2013;22(4):190\u20135.","journal-title":"Diagn Mol Pathol"},{"key":"2999_CR92","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/14737159.2016.1221345","volume":"16","author":"IA Cree","year":"2016","unstructured":"Cree IA. Progress and potential of RAS mutation detection for diagnostics and companion diagnostics. Expert Rev Mol Diagn. 2016;16:1067\u201372.","journal-title":"Expert Rev Mol Diagn"},{"issue":"7598","key":"2999_CR93","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/532166a","volume":"532","author":"C Willyard","year":"2016","unstructured":"Willyard C. Cancer therapy: an evolved approach. Nature. 2016;532(7598):166\u20138.","journal-title":"Nature"},{"issue":"9","key":"2999_CR94","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/cgt.2015.39","volume":"22","author":"M Dietel","year":"2015","unstructured":"Dietel M, et al. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. Cancer Gene Ther. 2015;22(9):417\u201330.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"2999_CR95","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2217\/bmm.14.84","volume":"9","author":"CP Milne","year":"2015","unstructured":"Milne CP, et al. Complementary versus companion diagnostics: apples and oranges? Biomark Med. 2015;9(1):25\u201334.","journal-title":"Biomark Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2999-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T11:15:50Z","timestamp":1692616550000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-016-2999-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,5]]},"references-count":95,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2999"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2999-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,5]]},"article-number":"10"}}